You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫藥業(002422.SZ)披露年報:營收165億元及研發投入達15億元 擬10派3.188元
格隆匯 04-27 21:28

格隆匯 4 月 27日丨科倫藥業(002422.SZ)發佈2020年年度報吿,實現營業收入164.64億元,歸屬於上市公司股東的淨利潤8.29億元,歸屬於上市公司股東的扣除非經常性損益的淨利潤6.28億元;經營活動產生的現金流量淨額22.19億元;基本每股收益0.58元,擬每10股派發現金紅利3.188元(含税)。

報吿期內,公司研發投入15.16億元,同比增長12.24%,研發投入佔銷售收入的比重達到9.21%2020年度23項產品獲批上市,24項申報生產,有力地支持了公司的項目研發和創新發展。自2017年至2021424日,獲批上市75項,開展了20項創新藥物臨牀研究,有57項處於申報生產階段。

公司研發創新取得的專利成果保持穩定增長,截至20201231日,已累計申請國內外專利4032項,累計獲得專利授權2573項。

截至20201231日,公司擁有606個品種共1,020種規格的醫藥產品,其中有130個品種共300種規格的輸液產品、414個品種共656種規格的其它劑型醫藥產品、62個品種共64種規格的原料藥。以及12個品種的抗生素中間體,6個品種共13種規格的醫用器械。

公司生產的藥品按臨牀應用範圍分類,共有25個劑型606種藥品。其中,進入《國家基本藥物目錄(2018年版)》的藥品為128種,被列入OTC品種目錄的藥品為82種,被列入《國家醫保目錄(2020年版)》的藥品為273種。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account